公开(公告)号：US20140039059A1

公开(公告)日：2014-02-06

申请号：US14047391

申请日：2013-10-07

Applicant: ITALFARMACO SPA

Inventor： Tiziano Oldoni ,  Paolo Mascagni ,  Alessandro Rambaldi ,  Tiziano Barbui

IPC: A61K31/167 ,  A61K45/06

CPC classification number: A61K31/27 ,  A61K31/00 ,  A61K31/16 ,  A61K31/167 ,  A61K31/18 ,  A61K45/06

Abstract: The use of substances capable of inhibiting one or more enzymes of the histone deacetylase family (histone deacetylase inhibitors) for the therapeutic treatment of Philadelphia-negative myeloproliferative syndromes (polycythemia vera, essential thrombocythemia or idiopathic myelofibrosis) is described. The dosage of the above-mentioned substances is significantly lower than that normally used for the care of other tumour syndromes and may be from 10 to 150 mg/day/patient.

Abstract translation: 描述了能够抑制组蛋白脱乙酰酶家族的一种或多种酶（组蛋白脱乙酰酶抑制剂）用于费城阴性骨髓增生综合征（真性红细胞增多症，原发性血小板增多症或特发性骨髓纤维化）的治疗性治疗的物质的使用。 上述物质的剂量明显低于通常用于其他肿瘤综合征的治疗剂量，并且可以为10至150mg /天/患者。

公开(公告)号：US09522127B2

公开(公告)日：2016-12-20

申请号：US14047391

申请日：2013-10-07

Applicant: ITALFARMACO SPA

Inventor： Tiziano Oldoni ,  Paolo Mascagni ,  Alessandro Rambaldi ,  Tiziano Barbui

IPC: A61K31/00 ,  A61K31/16 ,  A61K31/167 ,  A61K45/06 ,  A61K31/18

CPC classification number: A61K31/27 ,  A61K31/00 ,  A61K31/16 ,  A61K31/167 ,  A61K31/18 ,  A61K45/06

Abstract: Method of treating Philadelphia-negative myeloproliferative syndromes in a patient suffering from such syndromes. The method is carried out by administering to the patient diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl -methyl]-ammonium chloride, or other pharmaceutically acceptable salts and/or solvates, in a daily dosage amount of from 10 to 150 mg per patient.

Abstract translation: 在患有这种综合征的患者中治疗费城阴性骨髓增生综合征的方法。 该方法通过以日剂量给予患者二乙基 - [6-（4-羟基氨基甲酰基 - 苯基氨基甲酰氧基甲基） - 萘-2-基 - 甲基] - 氯化铵或其他药学上可接受的盐和/或溶剂合物 每位患者10至150mg。